# Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/comparison-of-recist-1-1-and-irecist-in-patients-treated-with-immune-checkpoint/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Hyo Jung Park,Gun Ha Kim,Kyung Won Kim,Choong Wook Lee,Shinkyo Yoon,Young Kwang Chae,Sree Harsha Tirumani,Nikhil H. Ramaiya |
| Citations | 39 |
| DOI | 10.3390/cancers13010120 |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://www.mdpi.com/2072-6694/13/1/120/pdf?version=1609489647 |
| OpenAlex ID | https://openalex.org/W3114370787 |
| PMID | 33561078 |
| Type | review |
| Year | 2021 |

## Paper authors

- [Shinkyo Yoon](https://scholariq.org/researchers/shinkyo-yoon/)

## Paper journal

- [Cancers](https://scholariq.org/journals/cancers/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.